Prophylaxis of Febrile Neutropenia With Lactoferrin in Oncohematologic Children Undergoing Induction Chemotherapy

Phase II Study for Prophylaxis of Febrile Neutropenia by Supplementation With Lactoferrin in Oncohematologic Children Undergoing High-intensity Chemotherapy Treatment

Test, in a randomized phase II trial, the safety and efficacy of lactoferrin prophylaxis in preventing the occurrence of febrile neutropenia and sepsis, with particular regard to forms due to multidrug-resistant Gram-negative bacteria.

Inclusion Criteria:

Patients with severe neutropenia lasting >7 days:

• non-High Risk Acute Lymphoblastic Leukemia ( ALL) under induction treatment
• Acute Myeloid Leukemia (AML) (first two cycles of treatment)
• B cell - non Hodgkin Lymphoma (NHL) Ability to take oral lactoferrin therapy and perform the diagnostic tests established by the protocol

Exclusion Criteria:

• Previous chemotherapy treatments
• Past history of colonization/infection by multidrug-resistant pathogens
• Inability to take LF by mouth
• Refusal to participate in the study